Rallybio CFO Jonathan Lieber shifts to part-time role ahead of Avenzo merger

Rallybio Corporation disclosed in a Form 8-K dated September 8, 2026 that Chief Financial Officer Jonathan Lieber will move to part-time employment status effective September 15, 2026. Rallybio said Lieber will continue to serve as Chief Financial Officer and Principal Financial Officer, keeping the same duties and authority he held before the change.¹

Under the arrangement, described in an Employment Side Letter between Lieber, Rallybio and Rallybio, LLC, Lieber will earn a base salary of $420,000 after the transition date and remain eligible for Rallybio's benefit plans, though he will not receive an annual bonus for 2026 or for any later year he remains employed.¹

The filing ties the end of his tenure to a pending corporate transaction. Lieber's employment will end when Rallybio's planned combination with Avenzo Therapeutics, Inc. is completed, under a merger agreement signed May 31, 2026 involving Rallybio, Avenzo and a Rallybio subsidiary, unless the arrangement ends earlier at either party's initiative.¹

If his employment ends under that scenario, Lieber would be entitled to severance under his original 2023 employment agreement and its later amendment, both previously filed with the SEC.¹

The company noted that the summary of the Employment Side Letter in the filing is not complete and is qualified by the full text of the letter, which is attached as an exhibit.¹ The 8-K was signed by Lieber himself, in his capacity as Chief Financial Officer, on September 9, 2026.